ARAY - Accuray Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.6900
+0.0100 (+0.37%)
As of 2:55PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.6800
Open2.6800
Bid2.6900 x 800
Ask2.7000 x 3100
Day's Range2.6500 - 2.7300
52 Week Range2.3500 - 5.4000
Volume244,453
Avg. Volume568,247
Market Cap239.476M
Beta (3Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.1880
Earnings DateJan 20, 2020 - Jan 24, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.88
  • Is Accuray Incorporated (NASDAQ:ARAY) Trading At A 30% Discount?
    Simply Wall St.

    Is Accuray Incorporated (NASDAQ:ARAY) Trading At A 30% Discount?

    In this article we are going to estimate the intrinsic value of Accuray Incorporated (NASDAQ:ARAY) by estimating the...

  • Hedge Funds Are Crazy About Accuray Incorporated (ARAY)
    Insider Monkey

    Hedge Funds Are Crazy About Accuray Incorporated (ARAY)

    It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]

  • First Asia-Pacific hospital treats patients with RayStation and Radixact
    PR Newswire

    First Asia-Pacific hospital treats patients with RayStation and Radixact

    SUNNYVALE, California, Nov. 7, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) – Thailand's Lopburi Cancer Hospital, a center of excellence for cancer treatment, is the first in the Asia-Pacific region to clinically use the combination of RaySearch's treatment planning system RayStation® with Accuray's Radixact® Treatment Delivery System. Lopburi has a focus on innovation and has been designated a national center of excellence for cancer treatment.

  • PR Newswire

    Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules

    SUNNYVALE, Calif. , Nov. 6, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Suzanne Winter , the company's ...

  • Thomson Reuters StreetEvents

    Edited Transcript of ARAY earnings conference call or presentation 29-Oct-19 8:30pm GMT

    Q1 2020 Accuray Inc Earnings Call

  • Medtronic Introduces Robotics Challenger to Intuitive System
    GuruFocus.com

    Medtronic Introduces Robotics Challenger to Intuitive System

    A move aimed at strengthening the medical device firm’s position in the surgical market Continue reading...

  • Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained
    Zacks

    Accuray (ARAY) Q1 Wider Than Expected, FY20 View Retained

    Accuray (ARAY) reiterates revenue and adjusted EBITDA view for fiscal 2020.

  • Accuray (ARAY) Reports Q1 Loss, Lags Revenue Estimates
    Zacks

    Accuray (ARAY) Reports Q1 Loss, Lags Revenue Estimates

    Accuray (ARAY) delivered earnings and revenue surprises of -10.00% and -4.03%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • PR Newswire

    Accuray Reports Fiscal 2020 First Quarter Financial Results

    SUNNYVALE, Calif. , Oct. 29, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported its financial results for the first quarter of fiscal 2020 ended September 30, 2019 . Recent Company ...

  • PR Newswire

    Accuray Appoints Medtech Veteran Suzanne Winter as Chief Commercial Officer

    SUNNYVALE, Calif., Oct. 21, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that Suzanne Winter has joined the company as Senior Vice President, Chief Commercial Officer effective October 21, 2019. Ms. Winter will have global responsibility for the commercial function reporting to Accuray's President and CEO, Joshua Levine. Ms. Winter has more than 25 years of medical technology experience in senior executive roles spanning general management, commercial operations, and strategic business development across a range of healthcare industry segments, including radiology, neurology and surgery.

  • Accuray (NASDAQ:ARAY) Has A Somewhat Strained Balance Sheet
    Simply Wall St.

    Accuray (NASDAQ:ARAY) Has A Somewhat Strained Balance Sheet

    Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

  • PR Newswire

    Accuray To Report Fiscal 2020 First Quarter Financial Results on October 29, 2019

    SUNNYVALE, Calif. , Oct. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report results for its first quarter ended September 30, 2019 on Tuesday, October 29, 2019 after the market close. ...

  • AngioDynamics Boosts VIT Product Portfolio With New Buyout
    Zacks

    AngioDynamics Boosts VIT Product Portfolio With New Buyout

    AngioDynamics (ANGO) is likely to see an expansion of its already existing VIT product portfolio with the buyout of Eximo Medical.

  • Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform
    Zacks

    Luminex Gets FDA Nod for ARIES MRSA Assay, Boosts Platform

    Luminex (LMNX) receives FDA clearance for the ARIES MRSA assay, which is likely to provide a boost to the company's ARIES platform.

  • Is It Time To Consider Buying Accuray Incorporated (NASDAQ:ARAY)?
    Simply Wall St.

    Is It Time To Consider Buying Accuray Incorporated (NASDAQ:ARAY)?

    Accuray Incorporated (NASDAQ:ARAY), which is in the medical equipment business, and is based in United States, saw a...

  • PR Newswire

    Accuray Educates Radiation Oncology Practices on the Potential Impact of the Proposed Alternative Payment Model (RO-APM)

    SUNNYVALE, Calif., Sept. 19, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) today published an informational guide designed to help radiation oncology practices understand the complexities of the much-anticipated proposed Medicare & Medicaid reimbursement changes. Titled, "Thriving Under the Radiation Oncology Alternative Payment Model: A Definitive Guide to a New Reality," the guide aims to help radiation oncology professionals understand the changes outlined in the Radiation Oncology – Alternative Payment Model (RO-APM). "We believe that the proposed alternative payment model will reshape economic realities and evolve clinical best practices for radiation oncologists," said Joshua H. Levine, President and Chief Executive Officer of Accuray.

  • The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks
    Zacks

    The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks

    A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.

  • Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome
    Zacks

    Accuray's (ARAY) CyberKnife Delivers Improved Patient Outcome

    Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.

  • PR Newswire

    Data Published in The Lancet Oncology Suggest CyberKnife® Prostate Patients Experienced Lower Levels of Acute Genitourinary Toxicity (Grade 2 or Higher) Than Patients Treated on a Conventional Linear Accelerator

    SUNNYVALE, Calif., Sept. 17, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announces that The Lancet Oncology, a high impact and leading global peer-reviewed oncology journal, has published patient- and clinician-reported outcomes data from the PACE — Prostate Advances in Comparative Evidence — trial in its most recent issue. While further investigation is planned, data reported in the journal indicate that the level of grade 2 or higher acute genitourinary toxicity in the stereotactic body radiation therapy (SBRT) arm of the trial is lower for patients treated with the Accuray CyberKnife® System than it is for patients treated on a conventional linear accelerator. SBRT involves the delivery of very high doses of externally-administered radiation over a small number of treatment sessions, offering convenience for patients, compared to conventional radiation therapy which requires a substantially longer course of treatment.

  • PR Newswire

    China Announces Tariff Exclusion for Medical Linear Accelerators

    SUNNYVALE, Calif., Sept. 16, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced that, on September 11, 2019, China's Customs Tariff Commission of the State Council issued a tariff exemption for medical linear accelerators.  The tariff exemption, which will be effective September 17, 2019 and is scheduled to last for one year, applies to the additional tariffs China imposed on U.S. products effective as of August 23, 2018.  Accuray expects to benefit from such tariff exemption. "We applaud the recent decision to exempt medical linear accelerators," said Josh Levine, president and chief executive officer, Accuray.

  • Why Is Accuray (ARAY) Down 1% Since Last Earnings Report?
    Zacks

    Why Is Accuray (ARAY) Down 1% Since Last Earnings Report?

    Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • PR Newswire

    Accuray Appoints Healthcare Veteran James M. Hindman to Board of Directors

    SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company's Board to nine members. Mr. Hindman, an experienced healthcare executive with a 30-year tenure at Allergan, Inc., is an accomplished financial executive with expertise in maximizing shareholder value. Mr. Hindman will serve on the Board's Audit Committee.

  • PR Newswire

    Geisinger Medical Center is First in Pennsylvania to Treat Cancer Patients with Accuray Radixact® System

    SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today that the Geisinger Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the innovative Radixact® System. The hospital, located in Danville, is part of Geisinger Health System, one of the United States' most innovative health services organizations. The system's speed, versatility and flexibility will enable the clinical team to provide a treatment option for virtually any case for which radiation therapy is prescribed, including large tumors or multiple tumors throughout the body, hard-to-reach tumors, and tumors that have recurred, including those in patients who may not be candidates for retreatment with traditional delivery systems.

  • Here's Why Investors Should Retain Accuray (ARAY) Stock Now
    Zacks

    Here's Why Investors Should Retain Accuray (ARAY) Stock Now

    Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.